Shots:

• Oncology to evaluate Ixempra (ixabepilone) in combination with DRP CDx for metastatic breast cancer in EU. Post the results of trial- Oncology has an exclusive option to in-license commercialization rights for Ixempra in EU
• The focus of the in-licensing agreement is to utilize Oncology Ventures’ Drug Response Prediction (DRP) biomarker platform for the enhancement of its oncology portfolio
• Ixempra (ixabepilone) is an anti-cancer (antineoplastic or cytotoxic) drug approved by the US FDA for metastatic breast cancer in 2007. In July-2015 R-Pharma acquired global rights for Ixempra from BMS and is marketed in the US- South America- Switzerland- and Lichtenstein

Ref: Oncology Venture | Image: Accelerace